Skip to main content

Psoriatic arthritis

      TNFi cycling vs. switching to IL-17Ai?
      Dr @AlexisOgdie et al from CorEvitas registry:
      PsA & axSpA cohort - switche
      1 month 3 weeks ago
      TNFi cycling vs. switching to IL-17Ai? Dr @AlexisOgdie et al from CorEvitas registry: PsA & axSpA cohort - switchers (TNFi to IL17i) had greater improvements in cDAPSA & BASDAI vs. cyclers (2nd TNF) Not stat significant but offers alternative Tx options @RheumNow #ACR24 abs585 https://t.co/8m347BRM75
      Dr. Catherine Bakewell @CatherineB27 shares the preliminary ACR guidelines on ultrasound imaging in psoriatic arthritis
      Dr. Catherine Bakewell @CatherineB27 shares the preliminary ACR guidelines on ultrasound imaging in psoriatic arthritis covering 4 domains, detailed PICOs covering the early phase, diagnosis, assessment covering the domains of PsA @RheumNow #ACR24 https://t.co/DoHE1rsSGf
      Great summary of treatment choices in PsA:
      1. Identify domain involved
      2. Identify comorbidities/pt preferences
      3. Still
      1 month 3 weeks ago
      Great summary of treatment choices in PsA: 1. Identify domain involved 2. Identify comorbidities/pt preferences 3. Still unmet needs for ttx in inflammatory eye disease #ACR24 @rheumnow https://t.co/1WMnkDYvip
      Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients
      1 month 3 weeks ago
      Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients! Don’t forget the 5Ms! 🧠Mind (cog/mood) 💊Medication (PIM) 🏃‍♀️Mobility 👉Multi-complexity 💪🏻Matters most (pt priority) @RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX
      Musculoskeletal ultrasound (MSUS) has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis…
      ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and…
      RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by
      1 month 3 weeks ago
      RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
      Pain in PsA = predictor of disability and QoL

      TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated
      1 month 3 weeks ago
      Pain in PsA = predictor of disability and QoL TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated biomarkers vs PBO @RheumNow #ACR24 Abstract #2366 https://t.co/DAgmdmmTE0
      ×